• 1
    Mathews R., Hall W., Carter A. Direct-to-consumer genetic testing for addition susceptibility: a premature commercialisation of doubtful validity and value. Addiction 2012; 107: 20692074.
  • 2
    Haddow J., Palomaki G. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M. J. , Little J. , Burke W. , editors. Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. New York: Oxford University Press; 2003, p. 217233.
  • 3
    Grosse S. D., Khoury M. J. What is the clinical utility of genetic testing? Genet Med 2006; 8: 448450.
  • 4
    Janssens A. C., Gwinn M., Bradley L. A., Oostra B. A., van Duijn C. M., Khoury M. J. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet 2008; 82: 593599.
  • 5
    Burke W., Laberge A. M., Press N. Debating clinical utility. Public Health Genomics 2010; 13: 215223.
  • 6
    Ledley F. A consumer charter for genomic services. Nat Biotechnol 2002; 20: 767.
  • 7
    Borry P., Cornel M. C., Howard H. C. Where are you going, where have you been. Direct-to-consumer genetic tests for health purposes. J Commun Genet 2010; 1: 101106.
  • 8
    Foster M. W., Mulvihill J. J., Sharp R. R. Evaluating the utility of personal genomic information. Genet Med 2009; 11: 570574.
  • 9
    Borry P., van Hellemondt R. E., Sprumont D., Jales C. F., Rial-Sebbag E., Spranger T. M. et al. Legislation on direct-to-consumer genetic testing in seven European countries. Eur J Hum Genet 2012; doi:10.1038/ejhg.2011.278.
  • 10
    Howard H. C., Borry P. Europe and direct-to-consumer genetic tests. Nat Rev Genet 2012; 13: 146.
  • 11
    European Society of Human Genetics. Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 2010; 18: 12711273.
  • 12
    Bloss C. S., Darst B. F., Topol E. J., Schork N. J. Direct-to-consumer personalized genomic testing. Hum Mol Genet 2011; 20: 132141.
  • 13
    Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, Watkinson C et al. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst Rev 2010; (10): CD007275.
  • 14
    Tercyak K., Peshkin B. N., Wine L. A., Walker L. R. Interests of adolescents in genetic testing for nicotine addiction susceptibility. Prev Med 2006; 42: 6065.
  • 15
    Claassen L., Henneman L., Weijden T. V., Marteau T. M., Timmermans D. R. Being at risk for cardiovascular disease: perceptions and preventive behavior in people with and without a known genetic predisposition. Psychol Health Med 2012; DOI:10.1080/13548506.2011.644246.